BioCatalyst

OLMA — Olema Pharmaceuticals, Inc. catalysts

1 verified catalyst event(s) for Olema Pharmaceuticals, Inc. (ticker OLMA). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-06-30 — OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-06-30
in 8d
ESTIMATED
 READOUT
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan
Phase 3 · Breast Cancer, Advanced Breast Cancer
 OLMA Olema Pharmaceuticals, Inc. Palazestrant, Fulvestrant, Anastrozole, ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.